Announcement PDF RNS Number : 3576M Shield Therapeutics PLC 21 September 2021 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Investor presentation Hardman & Co Life Sciences Investor Forum London, UK, 21 September, 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces Greg Madison, CEO of Shield, will be presenting at the Hardman & Co Life Sciences Investor Forum on Thursday 23 September 2021. The webinar event will begin at 17:00 (BST) and investors can register to attend here: https://hardman-co.com/p/49CL-HU2/join-our-webinar No new material information will be disclosed at this event and the presentation will be made available on the Company website shortly after the event. For further information please contact: Shield Therapeutics plc Greg Madison, CEO Hans-Peter Rudolf, CFO Nominated Adviser and Joint Broker Peel Hunt LLP James Steel/Christopher Golden Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore Financial PR & IR Advisor Walbrook PR www.shieldtherapeutics.com +44 (0) 191 511 8500 +44 (0)20 7418 8900 +44 (0)20 7220 0500 +44 (0)20 7933 8780 or shield@walbrookpr.com Paul McManus/Lianne Cawthorne About Shield Therapeutics plc Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), a novel, stable, non- salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. Accrufer® has been launched in the US in July 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRALMMITMTATBBB